Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.46 |
| ▸ | HTR2B | P41595 | 6/20 | 0.46 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078060 | 0.88 | F2 (0.49) | HTR2CHTR2BGID4KDM4EF2 | |
| SCHEMBL6077679 | 0.84 | F2 (0.47) | HTR2CHTR2BGID4HTR2AKDM4E | |
| SCHEMBL6920702 | 0.76 | F2 (0.43) | HTR2CF2CYP3A4 | |
| SCHEMBL6920320 | 0.74 | F2 (0.43) | F2CYP3A4 | |
| SCHEMBL6920326 | 0.74 | F2 (0.43) | F2CYP3A4 | |
| SCHEMBL6919448 | 0.73 | F2 (0.46) | F2CYP3A4 | |
| SCHEMBL6914966 | 0.73 | F2 (0.46) | F2CYP3A4 | |
| SCHEMBL6914976 | 0.73 | F2 (0.46) | F2CYP3A4 | |
| SCHEMBL6077720 | 0.73 | F2 (0.50) | F2P2RX7 | |
| SCHEMBL6077558 | 0.72 | F2 (0.59) | HTR2CF2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | HTR2C 2150/4885HTR2B 1138/4885GID4 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.